You are here: Home » Markets » News
Business Standard

Healthcare services stocks rally; Thyrocare up 35% in 2 days post Q2 update

Thyrocare Technologies, Metropolis Healthcare and Dr. Lal PathLabs, hitting their respective record highs, were up 9 per cent to 17 per cent on the BSE in intra-day trade.

Thyrocare Technologies | Buzzing stocks | Markets

SI Reporter  |  Mumbai 

Shares of Thyrocare Technologies soared 17 per cent to Rs 1,038.60; zooming 35 per cent in the past two trading days.

Shares of healthcare services companies were on a roll, surging by up to 17 per cent on the BSE in intra-day trade on Wednesday on the expectation of strong earnings in the July-September quarter (Q2FY21).

Thyrocare Technologies, Metropolis Healthcare, and Dr. Lal PathLabs hit their respective record highs and were up 9 per cent to 17 per cent on the BSE in intra-day trade. In comparison, the S&P BSE Sensex was up 0.72 per cent at 39,860 points at 10:49 am.

Shares of soared 17 per cent to Rs 1,038.60; zooming 35 per cent in the past two trading days after the company on Tuesday said it reported nearly 37 per cent year-on-year and over 100 per cent sequential growth in aggregate revenue for the quarter ended September 2020 (Q2FY21).

“Q2FY21 has witnessed a motivating number and increased turnover of Covid-PCR and Covid-Antibody testing, and the aggregate revenue for the quarter has increased by about 37 per cent compared to Q2FY20. The low revenue in Q1FY21 has bounced back in Q2FY21 with a very healthy growth of 171 per cent over the trailing quarter,” said in a statement.

"The company has done more than 4 lakh Covid-19 RT-PCR test and more than 3.20 lakh Covid antibody test as on September 30, 2020. The Company has also started RT-PCR tests from its laboratory situated at Gurgaon, Delhi, and will create the same kind of facilities at Banglore and Kolkata. With non-Covid tests coming back to track, we anticipate a need for more capacity and facilities," it said.

has rallied nearly 9 per cent to Rs 2,117.55 on the BSE. The stock has gained 18 per cent in the past three trading days after the company said it has achieved the highest ever quarterly revenue in Q2FY21.

The revenue for Q2FY21 has nearly doubled from Q1FY21 and has grown by around 25 per cent from Q2FY20 levels. In September 2020, revenue growth stood at around 40 per cent as compared to September 2019 due to an increase in Covid testing month-over-month and improving non-Covid business performance.

With scale-up of non-Covid business, sustained cost management measures as well as operating leverage on account of a significant uptick in revenue, the EBITDA margins in Q2FY21 have improved over Q2FY20, the company said.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, October 07 2020. 11:00 IST